Akèy › Sipwa › North Carolina › Wilmington
Etid klinik pou Sipwa nan Wilmington, NC
11 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Wilmington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
- Accellacare - Tradd Court - Wilmington /ID# 282200, Wilmington
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Ap rekriteFaz 2
- TMA Headlands, Wilmington
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Ap rekriteFaz 3
- Accellacare and KDCILM, LLC, Wilmington
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Ap rekriteFaz 3
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Ap rekriteFaz 3
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Ap rekriteFaz 3
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Ap rekriteFaz 3
- Accellacare - Wilmington - 1917 Tradd Court, Wilmington
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Ap rekriteFaz 3
- KDCILM, LLC & Accellacare US, Inc., Wilmington
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Ap rekriteFaz 3
- Accellacare Research of Wilmington, Wilmington
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Wilmington
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Ap rekriteFaz 1
- Accellacare, Wilmington
Etid Sipwa nan lòt vil
- San Antonio, TX34 etid
- Houston, TX33 etid
- Chicago, IL28 etid
- Orlando, FL27 etid
- Las Vegas, NV23 etid
- Miami, FL23 etid
- Atlanta, GA20 etid
- Dallas, TX20 etid
- New York City, NY19 etid
- Jacksonville, FL19 etid
- Washington, DC19 etid
- Austin, TX18 etid
Lòt etid nan Wilmington
- Obèsite15 etid
- Dyabèt Tip 28 etid
- Ensifizyans kadyak6 etid
- Kolit Ulseratif4 etid
- Hypertension artérielle3 etid
- Maladi kadyovaskilè3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.